Do you want to read an article? Please log in or register.
Discovery of Multi-Target Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) for Associated Pulmonary Diseases.
Related content
Pulmonary Fibrosis
Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients
Pediatr Pulmonol.
Bruch BA, Singh SB, Ramsey LJ, Starner TD
doi: 10.1002/ppul.24024.
First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results
Swiss Med Wkly.
Murer C, Huber LC, Kurowski T, Hirt A, Robinson CA, Bürgi U, Benden C
doi: 10.4414/smw.2018.14593.
Pulmonary Fibrosis
New treatments targeting the basic defects in cystic fibrosis
Presse Med.
Fajac I, Wainwright CE
doi: 10.1016/j.lpm.2017.01.024.
RECOMMENDED
Pulmonary Fibrosis
Targeting Proteases in Cystic Fibrosis Lung Disease: Paradigms, Progress, and Potential
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med.
McKelvey MC, Weldon S, McAuley DF, Mall MA, Taggart CC
doi: 10.1164/rccm.201906-1190PP.
Pulmonary Fibrosis
CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis
Ann Am Thorac Soc.
Gifford AH, Heltshe SL, Goss CH
doi: 10.1513/AnnalsATS.
RECOMMENDED
Pulmonary Fibrosis
Rapid Improvement After Starting Elexacaftor-tezacaftor-ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C, French Cystic Fibrosis Reference Network study group.
doi: 10.1164/rccm.202011-4153OC
RECOMMENDED
Pulmonary Fibrosis
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Duckworth A, Gibbons MA, Allen RJ, Almond H, Beaumont RN, Wood AR, Lunnon K, Lindsay MA, Wain LV, Tyrrell J, Scotton CJ
doi: 10.1016/S2213-2600(20)30364-7.Visit the original publication at ncbi.nlm.nih.gov
COMMENTED
COPDCough
The association between daily exacerbation symptoms and physical activity in patients with chronic obstructive pulmonary disease
Int J Chron Obstruct Pulmon Dis.
Crook S, Büsching G, Keusch S, Wieser S, Turk A, Frey M, Puhan MA, Frei A
doi: 10.2147/COPD.S156986.
Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children
PLoS Pathog.
Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, Turkovic L, Ranganathan SC, Boucher RC, Stick SM, Wolfgang MC
doi: 10.1371/